Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 9/20 | 0.43 |
| ▸ | BRD4 | O60885 | 4/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.40 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.40 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.40 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12841512 | 1.00 | SMO (0.43) | SMOBRD4GSK3BSMARCA2SMARCA4 | |
| SCHEMBL9931427 | 1.00 | SMO (0.43) | SMOBRD4GSK3BSMARCA2SMARCA4 | |
| SCHEMBL9968408 | 0.91 | SMO (0.38) | SMOMEN1KMT2A | |
| SCHEMBL9968457 | 0.91 | SMO (0.38) | SMOMEN1KMT2A | |
| SCHEMBL9932427 | 0.85 | SMO (0.59) | SMOMEN1KMT2A | |
| SCHEMBL9932004 | 0.84 | SMO (0.43) | SMOGSK3BSUV39H2MEN1KMT2A | |
| SCHEMBL9933004 | 0.84 | SMO (0.43) | SMOGSK3BSUV39H2MEN1KMT2A | |
| SCHEMBL9968441 | 0.82 | SMO (0.39) | SMOMEN1KMT2AFAAHEPHX2 | |
| SCHEMBL9968395 | 0.82 | SMO (0.39) | SMOMEN1KMT2AFAAHEPHX2 | |
| SCHEMBL9932918 | 0.82 | SMO (0.43) | SMOBRD4SMARCA2SMARCA4PBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | SMO, RB1, GLI1 | SMO 1/4885BRD4 21/4885GSK3B 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.